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The Role of Mast Cells in Acute 
Coronary Syndromes 
Theoharis C. Theoharides, Ph.D., M.D.
A B S T R A C T
OBJECTIVE: Review evidence supporting the role of mast cells in cardiovascular 
pathophysiology. BACKGROUND: Cardiovascular inflammation has emerged as a 
key pathogenetic factor in coronary artery disease (CAD) and myocardial ischemia 
reperfusion (IR) injury. IR complicates all forms of coronary artery revasculariza-
tion. Cardiac mast cells have been implicated in CAD, IR and myocardial infarc-
tion (MI) through the release of pro-arrhythmogenic and inflammatory mediators, 
especially interleukin-6 (IL-6), considered an independent risk factor. METHODS: 
We reviewed relevant literature and summarized our own findings. RESULTS: We 
showed that CAD is associated with high intracoronary release of IL-6. Acute stress 
triggers mast cell- dependent release of histamine and IL-6. Moreover, acute stress in 
ApoE -/- mice leads to ischemia. Mast cells express corticotropin-releasing-hormone 
(CRH) receptors, activation of which leads to selective release of vascular endothelial 
growth factor (VEGF), an isoform of which is vasodilatory. In a randomized prospec-
tive study, we investigated serum IL-6 levels and cardiac tissue susceptibility in the 
mast cell deficient (W/Wv) mice (n=12) and their normal littermates (+/+). When 
the left coronary artery (LCA) was ligated followed by 6 hr of reperfusion IL-6 levels 
increased significantly after reperfusion only in the +/+ mice, but not in mast cell 
deficient W/Wv mice; cardiac muscle viability was significantly higher in W/Wv than 
the +/+ mice. CONCLUSION: These results support targeting selective inhibition of 
cardiac mast cell activation as prophylactic therapy in clinical situations involving 
myocardial inflammation and/or revascularization.
1 .  S E L E C T I V E  R E L E A S E  O F  M A S T  C E L L  M E D I A T O R S
Mast cells derive from a distinct precursor in the bone marrow [1] and mature 
under local tissue microenvironmental factors [2]. Mast cells are necessary for the 
development of allergic reactions, through crosslinking of their surface receptors for 
IgE (FcεRI), leading to degranulation and the release of vasoactive, pro-inflammatory 
and nociceptive mediators that include histamine, cytokines and proteolytic enzymes 
[3,4] (Table 1). The multitude of mediators that could be secreted, especially in response 
to many non-immunologic triggers (Table 2) has given rise to new speculations about 
the possible role of mast cells in immune responses, especially acquired immunity [5] 
and inflammation [6].
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Unlike allergic reactions, mast cells are rarely seen to de-
granulate during autoimmune [7] or inflammatory processes 
[8]. Instead, mast cells can secrete mediators without overt 
degranulation [9], through differential or selective release [10], 
probably regulated by the action of distinct protein kinases 
on a unique phosphoprotein [11,12]. In such cases, mast cells 
undergo ultrastructural alterations of their electron dense 
granular core indicative of secretion, but without overt degran-
ulation, a process that has been termed “activation” [13-15] 
“intragranular activation” [16] or “piecemeal” degranulation 
[17]. Selective release has been reported for a number of me-
diators [18-20], especially serotonin [10], eicosanoids [21-23] or 
IL-6 [24-27]. In fact, we showed that interleukin-1 (IL-1) can 
stimulate human mast cells to release IL-6 selectively without 
degranulation, through a unique process utilizing 40-80 nm 
vesicles unrelated to the secretory granules (800-1000 nm) 
[28]. We also recently showed that corticotropin releasing 
hormone (CRH) secreted under stress can stimulate human 
mast cells through specific CRH receptors to release vascular 
endothelial growth factor (VEGF) selectively [29].
These findings suggest that mast cells may also be involved 
in inflammatory diseases [6,30] that include migraines [31] 
and cardiovascular disease [32].
2 .  C A R D I O V A S C U L A R  I N F L A M M A T I O N
Increasing evidence implicates acute psychological stress 
and cardiac mast cells in cardiovascular pathology, especially 
unstable angina and silent myocardial ischemia (MI). MI oc-
curring without angina on presentation now appears to be a 
sizable portion of the MI population [33-36]. Allergic angina 
and MI have also been reported [37]. Mast cells have also 
recently been implicated in coronary microembolization and 
cardiomyocyte apoptosis [38]. There is growing evidence 
that cardiac mast cells [39] participate in the development of 
atherosclerosis, coronary inflammation and cardiac ischemia. 
Mast cells have been identified in coronary arteries during 
spasm [40], and accumulate in the shoulder region of human 
coronary atheromas, especially in association with plaque 
rupture [32,41,42]. The human mast cell proteolytic enzyme 
chymase has been shown to be the main cardiac source of 
converting enzyme generating the coronary constrictor 
angiotensin II [43]. Chymase can also promote cholesterol 
removal from HDL and deposition on foam cells [44-46]. 
Mast cells tryptase can induce wider spread inflammation 
through stimulation of protease-activated receptors (PAR) 
[47]. Tryptase is also a biomarker in patients with stable CAD 
[48]. Cardiac mast cell-derived histamine [49] can constrict the 
coronaries [50] and can sensitize nerve endings [51]; this action 
is rendered probable by the recent findings showing adventitial 
mast cells localized close to nerve endings in atherosclerotic 
coronary arteries [52].
Acute stress induced rat cardiac mast cells activation docu-
mented morphologically [53] It was later shown that acute 
stress induced histamine release from mouse heart [54], as 
well as serum histamine and IL-6 elevations [54,55]; these 
were greater in apolipoprotein E (ApoE) knockout mice that 
develop atherosclerosis, but were still entirely dependent on 
mast cells [54,55]. These findings are significant since serum 
IL-6 elevations in patients with acute MI were shown to de-
rive primarily from the coronary sinus [56]. Both histamine 
[57] and IL-6 [58] are significant predictive risk factors of 
coronary events.
We also recently showed that ischemia reperfusion in mice 
TABLE 1. Mast cell Triggers
Antigen + IgE
Anaphylatoxins
CRH
IL-1
Immunoglobulin – free light chains
LPS
NGF
NT
SCF
SP
Superantigens
Ucn
VIP
Viral DNA sequences
FIGURE 1. Schematic representation of the sequence of events 
that may lead to cardiac mast cell activation and neurogenic 
inflammation, leading to CAD.
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increased serum IL-6 and myocardial necrosis, but not in W/
Wv mast cell deficient mice [59]. Such results have prompted 
editorials implicating mast cells CAD and MI [60].
C O N C L U S I O N
In summary, the mast cell has emerged as a unique im-
mune cell that could be activated by many non-immune pro-
TABLE 2. Mast Cell Mediators
Mediators  Main Pathophysiologic Effects
Prestored
Biogenic Amines
 Histamine Vasodilation, angiogenesis, mitogenesis, pain
 5-Hydroxytryptamine (5-HT, serotonin) Vasoconstriction, pain
Chemokines
 IL-8, MCP-1, MCP-3, MCP-4, RANTES Chemoattraction and tissue infiltration of leukocytes
Enzymes
 Arylsulfatases Lipid/proteoglycan hydrolysis
 Carboxypeptidase A Peptide processing
 Chymase Tissue damage, angiotensin II synthesis, cholesterol liberation
 Kinogenases Synthesis of vasodilatory kinins, pain
 Phospholipases Arachidonic acid generation
 Tryptase Tissue damage, activation of PAR, inflammation, pain
Peptides
 Corticotropin-releasing hormone (CRH) Inflammation, vasodilation
 Endorphins Analgesia
 Endothelin Sepsis
 Kinins (bradykinin) Inflammation, pain, vasodilation
 Somatostatin (SRIF) Anti-inflammatory (?)
 Substance P (SP) Inflammation, pain
 Vasoactive intestinal peptide (VIP) Vasodilation
 Urocortin Inflammation, vasodilation
 Vascular endothelial growth factor (VGEF) Neovascularization, vasodilation
Proteoglycans
 Chondroitin sulfate Cartilage synthesis, anti-inflammatory
 Heparin Angiogenesis, nerve growth factor stabilization
 Hyaluronic acid Connective tissue, nerve growth factor stabilization
De novo synthesized
Cytokines
 Interleukins (IL)-1,2,3,4,5,6,9,10,13,16 Inflammation, leukocyte migration, pain
 INF-ã; MIF; TNF-á Inflammation, leukocyte proliferation/activation
Growth Factors
 SCF, GM-CSF, b-FGF, NGF, VEGF Growth of a variety of cells
Phospholipid metabolites
 Leukotriene B4 LTB4  Leukocyte chemotaxis 
 Leukotriene C4 (LTC4) Vasoconstriction, pain
 Platelet activating factor (PAF)  Platelet activation, vasodilation 
 Prostaglandin D2 (PGD2) Bronchonstriction, pain
Nitric oxide (NO) Vasodilation
CRH= corticotropin-releasing hormone, TGF-â= transforming growth factor-â, CSF= colony stimulating factor, TNF-á= tumor necrosis 
factor-á, INFã= Interferon-ã, SRIF= somatomedin release inhibitory factor, somatostatin, MIF= macrophage inflammatory factor, GM-CSF= 
granulocyte monocyte-colony stimulating factor, b-FGF= fibroblast growth factor, NGF= nerve growth factor, SCF= Stem cell factor, VEGF= 
vascular endothelial growth factor.
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cesses, including acute stress [61,62], and could participate in 
CAD and MI (Figure 1).
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